Parida Shrutakirty, Das Matuli, Dash Snehalata, Chakraborty Shoubhik, Mohanty Soumyakanta, Dash Shovna
Pediatric Ophthalmology, Strabismus and Neuro-ophthalmology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND.
Ophthalmology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND.
Cureus. 2025 Jul 16;17(7):e88047. doi: 10.7759/cureus.88047. eCollection 2025 Jul.
The present study aims to evaluate the effect of low-dose atropine (0.01%) on choroidal thickness in children with progressive myopia. A secondary objective was to compare the rate of myopia progression between children treated with low-dose atropine (0.01%) and those receiving placebo eye drops (preservative-free carboxymethyl cellulose 0.5%) through changes in equivalent, axial length (AXL), and best-corrected visual acuity (BCVA).
A prospective case-control interventional study was conducted in the department of ophthalmology at a tertiary eye care center in eastern India.
A total of 87 children aged 5-16 years with bilateral progressive myopia were recruited and randomly assigned into two groups. Spherical equivalence, AXL, and choroidal thickness (sub-foveal and at 1500 and 3000 microns nasal and temporal to the fovea) were documented at baseline,1 month,3 months, and 6 months.44 children in group A received treatment with once-daily dosing of atropine at bedtime, while 43 children in group B received a placebo eyedrop.
Children in group A showed a significant increase in overall choroidal thickness at 3 and 6 months (11+/-9.67) and (18+/-13.43) microns, respectively, which showed a significant correlation with the progression of myopia (in terms of spherical equivalence and AXL).
Low-dose atropine induced a significant choroidal thickening effect, which was associated with slower progression of myopia in the treatment group.
本研究旨在评估低剂量阿托品(0.01%)对进行性近视儿童脉络膜厚度的影响。次要目的是通过等效球镜度、眼轴长度(AXL)和最佳矫正视力(BCVA)的变化,比较低剂量阿托品(0.01%)治疗的儿童与接受安慰剂滴眼液(0.5%无防腐剂羧甲基纤维素)的儿童之间的近视进展率。
在印度东部一家三级眼科护理中心的眼科进行了一项前瞻性病例对照干预研究。
共招募87名年龄在5至16岁的双侧进行性近视儿童,并随机分为两组。在基线、1个月、3个月和6个月时记录等效球镜度、眼轴长度和脉络膜厚度(黄斑中心凹下以及黄斑中心凹鼻侧和颞侧1500微米及3000微米处)。A组44名儿童在睡前每日一次滴用阿托品进行治疗,而B组43名儿童接受安慰剂滴眼液。
A组儿童在3个月和6个月时脉络膜总厚度分别显著增加(11±9.67)和(18±13.43)微米,这与近视进展(等效球镜度和眼轴长度方面)显著相关。
低剂量阿托品诱导了显著的脉络膜增厚效应,这与治疗组近视进展较慢相关。